Stockscreener 앱 받기
1.515
12.22%
0.165
시간 외 거래:
1.50
-0.015
-0.99%
전일 마감가:
$1.35
열려 있는:
$1.31
하루 거래량:
3.77M
Relative Volume:
1.98
시가총액:
$103.76M
수익:
$129.87M
순이익/손실:
$-44.09M
주가수익비율:
-1.8364
EPS:
-0.825
순현금흐름:
$-30.55M
1주 성능:
+19.29%
1개월 성능:
+13.06%
6개월 성능:
-45.50%
1년 성능:
-69.76%
1일 변동 폭
$1.195
$1.52
1주일 범위
$0.80
$1.52
52주 변동 폭
$0.80
$5.13
Neuronetics Inc Stock (STIM) Company Profile
명칭
Neuronetics Inc
전화
877-600-7555
주소
3222 PHOENIXVILLE PIKE, MALVERN, PA
Compare STIM vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
STIM
Neuronetics Inc
|
1.515 | 92.46M | 129.87M | -44.09M | -30.55M | -0.825 |
|
ABT
Abbott Laboratories
|
107.19 | 188.52B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
339.76 | 132.34B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.87 | 111.97B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
69.89 | 105.77B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
82.46 | 47.98B | 6.07B | 1.06B | 1.34B | 1.8063 |
Neuronetics Inc Stock (STIM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-10-13 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2021-10-13 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2021-01-22 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2020-02-06 | 개시 | BTIG Research | Buy |
| 2018-07-24 | 개시 | Canaccord Genuity | Buy |
모두보기
Neuronetics Inc 주식(STIM)의 최신 뉴스
STIM (NASDAQ: STIM) notice: proposed sale of 46,289 common shares - Stock Titan
Canaccord Genuity Group Lowers Neuronetics (NASDAQ:STIM) Price Target to $3.00 - MarketBeat
STIM: Neuronetics Analyst Rating UpdateMarch 19, 2026 | STIM Stock News - GuruFocus
Neuronetics, Inc. (NASDAQ:STIM) Q4 2025 Earnings Call Transcript - Insider Monkey
[Form 4] Neuronetics, Inc. Insider Trading Activity - Stock Titan
Neuronetics (STIM) EVP receives 33,750 performance-based common shares - Stock Titan
Neuronetics (STIM) CFO awarded 25,000 RSUs vesting from 2027 - Stock Titan
This New $7 Million Bet Targets a CNS Drug Maker With Phase 3 Trial Underway and 27% Stock Gain - AOL.com
Neuronetics to Spotlight Expanding Mental Health Therapies at Major Industry Forum - MSN
Canaccord cuts Neuronetics stock price target on valuation shift By Investing.com - Investing.com India
Neuronetics (NASDAQ:STIM) Major Shareholder Acquires 531,000 Shares - MarketBeat
Insider Buying: Jorey Chernett Acquires 531,000 Shares of Neuron - GuruFocus
This $6 Million Bet Adds a Brain Health Biotech to Portfolio Dominated by Clinical Stage Names - AOL.com
Neuronetics Insider Bought Shares Worth $615,960, According to a Recent SEC Filing - marketscreener.com
Neuronetics 10% Owner Purchased Shares Worth Over $615K - TradingView
Large Neuronetics (STIM) insider purchase adds 531,000 shares at $1.16 - Stock Titan
Large Neuronetics (STIM) holder discloses 6,985,404-share position - Stock Titan
Prenuvo CEO bets he can save lives and major healthcare spending by ‘inverting the pyramid’ - AOL.com
Canaccord cuts Neuronetics stock price target on valuation shift - Investing.com
Neuronetics, Inc. Stock Plummets to New 52-Week Low of $0.80 - Markets Mojo
[SCHEDULE 13G/A] Neuronetics, Inc. Amended Passive Investment Disclosure - Stock Titan
Neuronetics revenue up 86% to USD 41.8M in Q4 2025 - Medical Buyer
Neuronetics names Dan Reuvers as CEO effective March 23 By Investing.com - Investing.com India
According to the latest filing from the U.S. Securities and Exchange Commission (SEC), some existing shareholders of Neuronetics Inc. plan to sell up to 20.7 million shares of the company's common stock. - Bitget
Neuronetics (NASDAQ: STIM) registers resale of 20.7M shares by Madryn holders - Stock Titan
Neuronetics appoints Dan Reuvers as President and CEO - TipRanks
Neuronetics outlines >9% 2026 revenue growth target while piloting new TMS models and preparing for Compass therapy launch - MSN
Published on: 2026-03-18 12:34:36 - baoquankhu1.vn
STIM Volatility: Market Contemplates Latest Economic Pressures and Investor Positioning - StocksToTrade
Malvern-based Neuronetics appoints new CEO, revenue surges after acquisition - The Business Journals
Parian Ultreia reports 7.0% stake in Neuronetics (NASDAQ: STIM) — 4.84M shares - Stock Titan
Neuronetics CEO Transition & Financial Reporting Practices | Leadership UpdateNews and Statistics - IndexBox
Neuronetics, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Neuronetics Surges As Stock Price Experiences Notable Shift - timothysykes.com
Neuronetics Reports Record 2025 Financial Results, Greenbrook Clinic Growth, and 2026 Outlook with New CEO Appointment - Minichart
Neuronetics (STIM) Q4 2025 Earnings Transcript - The Globe and Mail
Neuronetics (STIM) Announces New CEO, Shares Surge - GuruFocus
Neuronetics Q4 Earnings Call Highlights - Yahoo Finance
Neuronetics earnings missed by $0.01, revenue topped estimates - Investing.com Canada
Earnings call transcript: Neuronetics Q4 2025 sees revenue growth, EPS miss - Investing.com
Neuronetics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Neuronetics 2025 Financial Results: Q4 Revenue $41.8M, Annual Loss $39MNews and Statistics - IndexBox
Neuronetics Appoints New CEO to Lead Next Growth Phase - TipRanks
NEURONETICS ($STIM) Releases Q4 2025 Earnings - Quiver Quantitative
Neuronetics names Dan Reuvers as CEO effective March 23 - Investing.com
Neuronetics (NASDAQ:STIM) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS - MarketBeat
Neuronetics : STIM Corporate Presentation March 2026 - marketscreener.com
Neuronetics: Q4 Earnings Snapshot - Barchart
Neuronetics appoints Dan Reuvers as president and chief executive officer - marketscreener.com
Neuronetics 2025 10-K: Revenue $149.2M, Net Loss $39.1M - TradingView
Neuronetics Q4 revenue rises, appointes Dan Reuvers as CEO - TradingView
Neuronetics Inc (STIM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.85%
1.86%
자본화:
|
볼륨(24시간):